Sage touts pos­i­tive ear­ly sig­nals in Alzheimer's. Will they be able to re­peat it in a blind­ed study?

Sage Ther­a­peu­tics on Fri­day un­corked what it sees as some pos­i­tive — al­beit ear­ly, and un­blind­ed — da­ta sug­gest­ing its lead neu­ropsy­chi­atric drug led to im­prove­ments in Alzheimer’s pa­tients. Now the re­al test will be see­ing if those re­sults hold up in a larg­er, blind­ed group.

“The study was de­signed first and fore­most for safe­ty, tol­er­a­bil­i­ty and PK,” Aaron Koenig, Sage’s VP of ear­ly clin­i­cal de­vel­op­ment, told End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER